Kläver Ruth, Sánchez Victoria, Damm Oliver S, Redmann Klaus, Lahrmann Elisabeth, Sandhowe-Klaverkamp Reinhild, Rohde Christian, Wistuba Joachim, Ehmcke Jens, Schlatt Stefan, Gromoll Jörg
Institute of Reproductive and Regenerative Biology, Centre of Reproductive Medicine and Andrology, University of Münster, Münster, Germany.
Department of Hematology and Oncology, University of Halle, Halle, Germany.
PLoS One. 2015 Feb 18;10(2):e0117839. doi: 10.1371/journal.pone.0117839. eCollection 2015.
Establishment and maintenance of the correct epigenetic code is essential for a plethora of physiological pathways and disturbed epigenetic patterns can provoke severe consequences, e.g. tumour formation. In recent years, epigenetic drugs altering the epigenome of tumours actively have been developed for anti-cancer therapies. However, such drugs could potentially also affect other physiological pathways and systems in which intact epigenetic patterns are essential. Amongst those, male fertility is one of the most prominent. Consequently, we addressed possible direct effects of two epigenetic drugs, decitabine and vorinostat, on both, the male germ line and fertility. In addition, we checked for putative transgenerational epigenetic effects on the germ line of subsequent generations (F1-F3). Parental adult male C57Bl/6 mice were treated with either decitabine or vorinostat and analysed as well as three subsequent untreated generations derived from these males. Treatment directly affected several reproductive parameters as testis (decitabine & vorinostat) and epididymis weight, size of accessory sex glands (vorinostat), the height of the seminiferous epithelium and sperm concentration and morphology (decitabine). Furthermore, after decitabine administration, DNA methylation of a number of loci was altered in sperm. However, when analysing fertility of treated mice (fertilisation, litter size and sex ratio), no major effect of the selected epigenetic drugs on male fertility was detected. In subsequent generations (F1-F3 generations) only subtle changes on reproductive organs, sperm parameters and DNA methylation but no overall effect on fertility was observed. Consequently, in mice, decitabine and vorinostat neither affected male fertility per se nor caused marked transgenerational effects. We therefore suggest that both drugs do not induce major adverse effects-in terms of male fertility and transgenerational epigenetic inheritance-when used in anti-cancer-therapies.
建立和维持正确的表观遗传密码对于众多生理途径至关重要,而表观遗传模式紊乱会引发严重后果,例如肿瘤形成。近年来,已开发出能积极改变肿瘤表观基因组的表观遗传药物用于抗癌治疗。然而,这类药物也可能影响其他生理途径和系统,而完整的表观遗传模式在这些途径和系统中至关重要。其中,男性生育能力是最突出的方面之一。因此,我们研究了两种表观遗传药物地西他滨和伏立诺他对雄性生殖系和生育能力的可能直接影响。此外,我们还检测了对后代(F1 - F3)生殖系的假定跨代表观遗传效应。成年雄性C57Bl/6小鼠亲本接受地西他滨或伏立诺他治疗,并进行分析,同时对这些雄性小鼠的三代未处理后代也进行了分析。治疗直接影响了多个生殖参数,如睾丸(地西他滨和伏立诺他)和附睾重量、附属性腺大小(伏立诺他)、生精上皮高度以及精子浓度和形态(地西他滨)。此外,给予地西他滨后,精子中多个位点的DNA甲基化发生了改变。然而,在分析处理过的小鼠的生育能力(受精、产仔数和性别比例)时,未检测到所选表观遗传药物对雄性生育能力有重大影响。在后代(F1 - F3代)中,仅观察到生殖器官、精子参数和DNA甲基化有细微变化,但对生育能力没有总体影响。因此,在小鼠中,地西他滨和伏立诺他既不影响雄性生育能力本身,也不会引起明显的跨代效应。所以我们认为,在抗癌治疗中使用这两种药物时,就雄性生育能力和跨代表观遗传遗传而言,不会诱导重大不良反应。